Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma
Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.
Cilta-cel reduced the risk of death by 45% compared with standard of care in patients with multiple myeloma, according to the CARTITUDE-4 study.
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to…
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.
The study’s results illustrate the effects of these abnormalities and the importance of screening.
The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.
We’ve joined others in writing to the Chancellor urging the Government to back R&D if it wants to achieve its ambitions for growth
The synergy between radiation therapy and systemic cancer therapies like immunotherapy has long been established, but new research from the Wen Jiang Laboratory leverages a…
Christiana Dinah, BSc, MBBS, MRes, London North West Healthcare NHS Trust, Harrow, UK, introduces the Sickle Eye Project, the first and largest multicenter study on…